These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 22574709)

  • 1. Metabolic responses to change in disease activity during tumor necrosis factor inhibition in patients with rheumatoid arthritis.
    Madsen R; Rantapää-Dahlqvist S; Lundstedt T; Moritz T; Trygg J
    J Proteome Res; 2012 Jul; 11(7):3796-804. PubMed ID: 22574709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
    Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
    Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
    El Miedany Y; Youssef SS; El Gaafary M
    J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
    Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
    Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan.
    Matsui T; Kuga Y; Kaneko A; Nishino J; Eto Y; Chiba N; Yasuda M; Saisho K; Shimada K; Tohma S
    Ann Rheum Dis; 2007 Sep; 66(9):1221-6. PubMed ID: 17369281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The platelet indices in patients with rheumatoid arthritis: mean platelet volume reflects disease activity.
    Yazici S; Yazici M; Erer B; Erer B; Calik Y; Ozhan H; Ataoglu S
    Platelets; 2010; 21(2):122-5. PubMed ID: 20050760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is pre-assessment for anti-TNF therapy in RA necessary in the UK? Analysis of DAS28 in six centres.
    Smith N; Gadsby K; Butt S; Carruthers D; Deeming A; Ledingham J; Fletcher M; Mulherin D; Roskell S; Kay L; Nicholl K; Cooper R; Worsley A; Deighton C
    Rheumatology (Oxford); 2007 Oct; 46(10):1557-9. PubMed ID: 17666440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of adalimumab therapy on disease activity and interferon-γ-mediated biochemical pathways in patients with rheumatoid arthritis.
    Kurz K; Herold M; Winkler C; Klotz W; Russe E; Fuchs D
    Autoimmunity; 2011 May; 44(3):235-42. PubMed ID: 21434757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate.
    Parker A; Izmailova ES; Narang J; Badola S; Le T; Roubenoff R; Ginsburg GS; Maier A; Coblyn JS; Shadick NA; Weinblatt ME
    J Rheumatol; 2007 Sep; 34(9):1817-22. PubMed ID: 17696278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.
    Braun-Moscovici Y; Markovits D; Zinder O; Schapira D; Rozin A; Ehrenburg M; Dain L; Hoffer E; Nahir AM; Balbir-Gurman A
    J Rheumatol; 2006 Mar; 33(3):497-500. PubMed ID: 16511906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis.
    Syngle A; Vohra K; Kaur L; Sharma S
    Scand J Rheumatol; 2009; 38(1):15-22. PubMed ID: 18766955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
    van der Pouw Kraan TC; Wijbrandts CA; van Baarsen LG; Rustenburg F; Baggen JM; Verweij CL; Tak PP
    Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis.
    Popa C; van den Hoogen FH; Radstake TR; Netea MG; Eijsbouts AE; den Heijer M; van der Meer JW; van Riel PL; Stalenhoef AF; Barrera P
    Ann Rheum Dis; 2007 Nov; 66(11):1503-7. PubMed ID: 17472994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hand function tests are important and sensitive tools for assessment of treatment response in patients with rheumatoid arthritis.
    Eberhardt K; Sandqvist G; Geborek P
    Scand J Rheumatol; 2008; 37(2):109-12. PubMed ID: 18415767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-course of health status in patients with rheumatoid arthritis during the first year of treatment with infliximab.
    Ban A; Inaba M; Furumitsu Y; Okamoto K; Yukioka K; Goto H; Nishizawa Y
    Biomed Pharmacother; 2010 Feb; 64(2):107-12. PubMed ID: 19944558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
    Ernestam S; Hafström I; Werner S; Carlström K; Tengstrand B
    J Rheumatol; 2007 Jul; 34(7):1451-8. PubMed ID: 17477470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased cortisol relative to adrenocorticotropic hormone predicts improvement during anti-tumor necrosis factor therapy in rheumatoid arthritis.
    Straub RH; Pongratz G; Cutolo M; Wijbrandts CA; Baeten D; Fleck M; Atzeni F; Grunke M; Kalden JR; Schölmerich J; Lorenz HM; Tak PP; Sarzi-Puttini P
    Arthritis Rheum; 2008 Apr; 58(4):976-84. PubMed ID: 18383357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.